An underground economy for unlicensed weight-loss medications is being driven by TikTok fitness influencers and vendors on messaging platforms, based on recent findings.
Experimental Drug Acquiring Popularity Via Social Media
Retatrutide, which is still in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Followers are encouraged to contact these accounts directly for source information, while also obtaining discount codes.
Thriving Trade on Messaging Platforms
Additionally, a robust market exists on messaging services, where communities with thousands of participants share “before and after” images, administration instructions and assertions of rapid British shipping. Sellers promote the substance there before directing customers to other platforms for transactions.
Understanding The Experimental Drug
Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Healthcare Professionals Express Worries
However, physicians and chemists have cautions that the sale of what remains an unlicensed drug in the UK is worrisome and could result in individuals administering substances of unknown origin.
Several experts said the popularity for the experimental drug could be connected to the increasing cost of licensed weight loss products such as Mounjaro.
Legal Status and Enforcement
Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be marketed or distributed for personal consumption under the British medical regulations.
Some content creators try to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still violate medicines, advertising, and customer regulations, risking fines, prosecution or prison.
Service Response and Content Elimination
According to the social media company, the platform has removed violative content and banned associated keywords and search suggestions. The company said it was committed to keeping the platform safe and investing in strengthening enforcement strategies.
Digital Trading Operations
Research also discovered groups with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” immediately displays groups with numerous of members, filled with photos of slimming results, glowing reviews and detailed instructions for mixing or injecting at home.
Within minutes of entering one group, a seller shared contact information, where most purchases take place. The vendor sent an instruction manual and promised delivery within 48 hours. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one inquired about body mass, health issues or past usage.
Product Details and Pricing
Within these communities, posts display dark colored packages with Royal Mail labels, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, prepared at residence with sterile water, or ready-to-use injectors typically sold at £160 for 20mg. When asked how long a injector should be used, vendors give conflicting answers ranging from a few weeks to “depends on your body”.
Platform Oversight and Security Actions
A spokesperson for Telegram said it regularly moderated dangerous material on its service including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are administering substances they can’t verify. Even if the research behind retatrutide is valid, these digital products may not include what they claim,” stated a pharmacy expert, the head of pharmacy at Chemist4U.
Dr Crystal Wyllie of an online medical service connected the increase in interest to current cost increases for approved slimming medications such as Mounjaro. “With prices increasing, patients are turning to social media. But counterfeit treatments are extremely dangerous. You cannot know what’s inside or whether the conditions they were produced in was clean,” she said.
Her staff has previously seen individuals harmed by personal administration from unconfirmed suppliers. “We understand the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These substances could be impure or improperly measured.”
Manufacturer Statement
A representative from Eli Lilly stated the substance was in third stage research studies and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a company investigational product not yet authorized … may expose users to possibly significant medical dangers”.
